Johnson & Johnson (J&J) has announced plans to separate its orthopedics business into an independent company. Operating under the DePuy Synthes name, the new entity is expected to become the world’s largest and most comprehensive orthopedics-focused firm.
The move is designed to allow J&J to concentrate on higher-growth, higher-margin areas within its MedTech and Innovative Medicine divisions. Through this spinoff, J&J expects each business to enhance revenue growth and strengthen operating performance.
The separation is anticipated to be completed within 18 to 24 months, pending regulatory, board, and employee consultation approvals. In fiscal year 2024, J&J’s orthopedics segment generated approximately $9.2 billion in sales.
